Last reviewed · How we verify

Urethritis — Treatment Landscape & Competitive Intelligence

Urethritis (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Urethritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Lignospan Forte Lidocaine Hydrochloride Fresenius Kabi local anesthetic, amide type neuronal membrane ionic channels 1948-01-01
Lignocaine Lignocaine University of Malaya 5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Lidocain Lidocain Bayer 5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
xylocain xylocain Saint-Joseph University 5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bayer · 1 drug in Urethritis
  2. Fresenius Kabi · 1 drug in Urethritis
  3. Saint-Joseph University · 1 drug in Urethritis
  4. University of Malaya · 1 drug in Urethritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Urethritis:

Cite this brief

Drug Landscape (2026). Urethritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/urethritis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing